Supplemental Table 1. Time course of therapeutic decisions and biological parameters

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Variables | March, 26 | March, 27 | March, 28 | March, 29 | March, 30 | March, 31 (6 am) | March, 31 (2.30 pm) | March, 31 (8.30 pm) | April, 1st | April, 2nd |
| Decisions | ICU, UFH | DC, PAE | UFH |  |  |  | IVIG  Argatroban |  |  |  |
| Platelet count, per mm3  INR  aPTT ratio  Fibrinogen, g/l | 61  1.2  1.0 | 77  1.3  3.4  2.1 | 107  1.2  1.2  2.4 | 121  1.2  2.8  3.5 | 145  1.2  4.2  4.3 | 108  1.3  4.8  4.4 | 123  1.8  2.0 | 134  1.7  2.3  4.2 | 154  1.9  2.3  4.6 | 195  2.1  2.5  5.6 |
| Plasma heparin, IU/ml  Plasma argatroban, mcg/ml |  | <0.1 | <0.1 | 0.3 | 0.6 | 0.3 | 0.2 | 0.5 | 0.9 | 0.9 |
| Anti-PF4 antibodies | 0.51 |  |  |  |  | 0.05 |  |  |  |  |

aPTT, activated partial thromboplastin time; DC, decompressive craniectomy; ICU, intensive care unit; INR, international normalized ratio; IVIG, intravenous immune globulin; PAE, peripheral arterial embolization; UFH, unfractionated heparin